Filing Details
- Accession Number:
- 0001209191-18-034208
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-05-30 17:29:52
- Reporting Period:
- 2018-05-30
- Accepted Time:
- 2018-05-30 17:29:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1659323 | Iterum Therapeutics Plc | ITRM | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1380178 | Shahzad Malik | C/O Iterum Therapeutics Plc, Blk 2 Fl. 3, Harcourt Centre, Harcourt St. Dublin L2 2 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2018-05-30 | 13,921 | $0.00 | 13,921 | No | 4 | C | Indirect | By Advent Life Sciences LLP |
| Ordinary Shares | Acquisiton | 2018-05-30 | 7,771 | $0.00 | 21,692 | No | 4 | C | Indirect | By Advent Life Sciences LLP |
| Ordinary Shares | Acquisiton | 2018-05-30 | 8,144 | $13.00 | 29,836 | No | 4 | P | Indirect | By Advent Life Sciences LLP |
| Ordinary Shares | Acquisiton | 2018-05-30 | 391,147 | $0.00 | 391,147 | No | 4 | C | Indirect | By Advent Life Sciences Fund II LP |
| Ordinary Shares | Acquisiton | 2018-05-30 | 218,338 | $0.00 | 609,485 | No | 4 | C | Indirect | By Advent Life Sciences Fund II LP |
| Ordinary Shares | Acquisiton | 2018-05-30 | 228,840 | $13.00 | 838,325 | No | 4 | P | Indirect | By Advent Life Sciences Fund II LP |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By Advent Life Sciences LLP |
| No | 4 | C | Indirect | By Advent Life Sciences LLP |
| No | 4 | P | Indirect | By Advent Life Sciences LLP |
| No | 4 | C | Indirect | By Advent Life Sciences Fund II LP |
| No | 4 | C | Indirect | By Advent Life Sciences Fund II LP |
| No | 4 | P | Indirect | By Advent Life Sciences Fund II LP |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Series B-1 Preferred Shares | Disposition | 2018-05-30 | 13,921 | $0.00 | 13,921 | $0.00 |
| Ordinary Shares | Series B-2 Preferred Shares | Disposition | 2018-05-30 | 7,771 | $0.00 | 7,771 | $0.00 |
| Ordinary Shares | Series B-1 Preferred Shares | Disposition | 2018-05-30 | 391,147 | $0.00 | 391,147 | $0.00 |
| Ordinary Shares | Series B-2 Preferred Shares | Disposition | 2018-05-30 | 218,338 | $0.00 | 218,338 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
- Securities are held by Advent Life Sciences LLP ("Advent"). The Reporting Person is a general partner of Advent, and disclaims beneficial ownership of the shares held by Advent except to the extent of his indirect pecuniary interest therein.
- The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
- Securities are held by Advent Life Sciences Fund II LP. Advent is the general partner of Advent Life Sciences Fund II LP and the Reporting Person is a general partner of Advent. The Reporting Person disclaims beneficial ownership of the shares held by Advent Life Sciences Fund II LP except to the extent of his indirect pecuniary interest therein.
- Not applicable.
Billionaire Hedge Funds
